ORION CORPORATION / INTERIM REPORT / JANUARY-JUNE 2013 / 30 July 2013 at
12:00 noon EEST
Orion's net sales in January-June 2013 totalled EUR 497 million (EUR 480 million
in January-June 2012).
* Operating profit was EUR 135 (144) million.
* Profit before taxes was EUR 134 (143) million.
* Equity ratio was 48% (55%).
* ROCE before taxes was 41% (52%).
* ROE after taxes was 43% (48%).
* Basic earnings per share were EUR 0.72 (0.77).
* Cash flow per share before financial items was 0.27 (0.50).
* The outlook estimate for 2013 remains unchanged. Orion estimates that in
2013 net sales will be at similar level to 2012 and that operating profit
will be slightly lower than in 2012.
* Novartis has submitted an application for marketing authorisation for
Stalevo in Japan.
ORION'S KEY FIGURES FOR THE REVIEW PERIOD
Q2/13 Q2/12 Change % Q1-Q2/13 Q1-Q2/12 Change % 2012
-------------------------------------------------------------------------------
Net sales, EUR million 248.0 232.8 +6.6% 497.4 480.2 +3.6% 980.4
-------------------------------------------------------------------------------
International
operations, EUR million 180.4 170.1 +6.1% 361.9 353.5 +2.4% 723.1
-------------------------------------------------------------------------------
% of net sales 72.7% 73.1% 72.8% 73.6% 73.8%
-------------------------------------------------------------------------------
Operating profit, EUR
million 61.1 65.3 -6.5% 135.2 143.9 -6.0% 278.3
-------------------------------------------------------------------------------
% of net sales 24.6% 28.1% 27.2% 30.0% 28.4%
-------------------------------------------------------------------------------
Profit before taxes, EUR
million 60.5 64.5 -6.2% 134.3 143.2 -6.2% 276.6
-------------------------------------------------------------------------------
% of net sales 24.4% 27.7% 27.0% 29.8% 28.2%
-------------------------------------------------------------------------------
Income tax expense, EUR
million 14.6 15.8 -7.4% 32.9 35.3 -7.0% 69.7
-------------------------------------------------------------------------------
R&D expenses, EUR
million 26.3 24.5 +7.6% 50.9 47.5 +7.2% 105.8
-------------------------------------------------------------------------------
% of net sales 10.6% 10.5% 10.2% 9.9% 10.8%
-------------------------------------------------------------------------------
Capital expenditure, EUR
million 17.3 15.0 +15.2% 36.7 23.3 +57.1% 46.8
-------------------------------------------------------------------------------
% of net sales 7.0% 6.5% 7.4% 4.9% 4.8%
-------------------------------------------------------------------------------
Assets total, EUR
million 887.7 729.0 +21.8% 835.7
-------------------------------------------------------------------------------
Equity ratio, % 48.1% 54.5% 61.0%
-------------------------------------------------------------------------------
Gearing, % 32.7% 24.0% -1.7%
-------------------------------------------------------------------------------
Interest-bearing
liabilities, EUR million 278.2 157.6 +76.6% 136.7
-------------------------------------------------------------------------------
Non-interest-bearing
liabilities, EUR million 182.1 174.1 +4.6% 189.5
-------------------------------------------------------------------------------
Cash and cash
equivalents and money
market investments, EUR
million 138.6 62.1 +123.0% 145.2
-------------------------------------------------------------------------------
ROCE (before taxes), % 40.9% 51.6% 45.9%
-------------------------------------------------------------------------------
ROE (after taxes), % 43.3% 48.1% 41.0%
-------------------------------------------------------------------------------
Basic earnings per
share, EUR 0.33 0.35 -5.9% 0.72 0.77 -6.0% 1.47
-------------------------------------------------------------------------------
Diluted earnings per
share, EUR 0.33 0.35 -5.9% 0.72 0.77 -6.0% 1.47
-------------------------------------------------------------------------------
Cash flow per share
before financial items,
EUR 0.19 0.23 -14.3% 0.27 0.50 -46.2% 1.23
-------------------------------------------------------------------------------
Equity per share, EUR 3.03 2.82 +7.5% 3.62
-------------------------------------------------------------------------------
Personnel at the end of
the period 3,663 3,609 +1.5% 3,486
-------------------------------------------------------------------------------
Average personnel during
the period 3,541 3,485 +1.6% 3,495
-------------------------------------------------------------------------------
Personnel expenses, EUR
million 110.9 107.0 +3.6% 214.8
-------------------------------------------------------------------------------
President and CEO Timo Lappalainen's review
"First half of the year progressed as anticipated"
"Our net sales were at similar level to the previous year and as expected our
operating profit was slightly lower than in 2012.
"As anticipated, deliveries of our Parkinson's drugs to Novartis further
declined. Total sales generated by Stalevo(®) and Comtess(®) products in Orion's
own sales organisation were also slightly down on the comparative period.
Despite intensifying generic competition, Parkinson's drugs will continue to be
an important product group for Orion. In June we received positive news in this
respect when Novartis announced its submission of an application for marketing
authorisation for Stalevo in Japan.
"We were able to compensate for the decrease in sales of Parkinson's drugs by
increasing sales from the rest of our product portfolio. We continued to
strengthen our market position by growing in many markets faster than growth of
the pharmaceuticals market as a whole. Our newest proprietary drug, the
intensive care sedative dexdor(®) (dexmedetomidine), maintained strong growth,
and Precedex(®) and Simdax(® )also developed well. Sales of the Easyhaler(®)
product family through our own sales network continued to grow strongly, but
total sales were slightly down on the previous year, mainly because of the
transitional period related to repatriation of product rights.
"Our Specialty Products business division continued to grow as expected and is
already almost as big as the Proprietary Products business division. Net sales
of the other divisions, especially Fermion, developed well during the review
period.
"During the summer we have continued negotiations with possible partners for the
next development phase for an alpha-2c adrenoceptor antagonist being developed
for the treatment of Alzheimer's disease and an androgen receptor antagonist for
the treatment of prostate cancer. In addition, we began Phase I clinical trials
with another alpha-2c adrenoceptor antagonist and a new COMT inhibitor.
"Orion Diagnostica held co-operation negotiations during the review period with
the aim of streamlining its operations and improving profitability by, among
other things, simplifying the product portfolio. As a result of the
negotiations, Orion Diagnostica's operations in Turku will cease and about 60
employees are being given notice of termination of employment. In addition,
about 20 employees will leave their posts through for example retirement or
ending of a fixed-term contract. We intend where possible to offer other
employment within the Group to those given notice. We recorded about EUR 1.6
million expenses related to the restructuring in the second quarter of the year.
"In the review period we announced that we were issuing a EUR 150 million bond
and would use the funds for the Group's general financing purposes. We are
preparing for, among other things, the many ongoing investment and production
reorganisation projects through which we will develop and ensure future growth,
delivery reliability and quality standards. The projects are temporarily
increasing production costs and decreasing production capacity, and that reduced
our margin in the first half of the year.
"Our outlook estimate, which can be found with the basis for it on pages 6-7 of
this report, remains unchanged. We estimate that our net sales will be at
similar level to the previous year and our operating profit will be slightly
lower than in 2012."
Events during the period
On 10 April Orion Diagnostica gave a negotiation proposal on streamlining
operations and reducing the number of personnel in Finland by no more than 80.
On 23 April the Board of Directors of Orion Corporation decided to acquire
shares in the Company as authorised by the Annual General Meeting on 19 March
2013.
On 3 June Orion Diagnostica's statutory co-operation negotiations were
completed.
On 4 June Orion announced that it would be issuing a EUR 150 million domestic
bond.
On 11 June the listing prospectus for Orion's bond was published.
Events after the period
On 25 July Orion announced that it had reached agreement with Mylan
Pharmaceuticals Inc. in the patent dispute concerning the proprietary drug
Stalevo(®).
News conference and teleconference
A news conference and teleconference on the published results will be held
today, Tuesday 30 July 2013, at 13:30 EEST in Hotel Kämp, address:
Pohjoisesplanadi 29, Helsinki. President and CEO Timo Lappalainen will give a
brief presentation in English on the financial review.
The event can be followed live as a webcast accessible via the Orion website at
www.orion.fi/en/investors. After the presentation, questions can be asked by
telephone in Finnish and English.
The teleconference code is 933428 and to participate in the teleconference,
please call:
from United States: +1 334 323 6203
from other countries: +44 (0)20 7162 0177
News conference recordings
A recording of the webcast of the event in English and a recording of the
presentation by the President and CEO in Finnish will be available on the Orion
website later today.
Financial report material
Financial reports and related presentation material are available at
www.orion.fi/en/investors promptly after publication. The website also has a
form for subscribing to Orion's releases.
Dates in Orion Calendar 2013-2014
Interim Report January-September 2013 Tuesday 22 October 2013
Capital Markets Day in Helsinki Wednesday 20 November 2013
Financial Statement Release for 2013 Tuesday 4 February 2014
Tuesday 25 March 2014
Annual General Meeting 2014
Interim Report January-March 2014 Tuesday 29 April 2014
Interim Report January-June 2014 Tuesday 29 July 2014
Tuesday 21 October 2014
Interim Report January-September 2014
The Financial Statements and the report of the Board of Directors 2013 will be
published on the Company's website at the latest in week 10/2014.
For additional information about the financial review:
Jari Karlson, CFO, tel. +358 10 426 2883
Tuukka Hirvonen, Communications Manager, tel. +358 10 426 2721 / GSM
+358 50 966 2721
www.orion.fi/en
www.orion.fi/en/investors
Financial review Q1-Q2/2013
Net sales
The Orion Group's net sales in January-June 2013 were EUR 497 million (EUR 480
million in January-June 2012). The net effect of currency exchange rates was EUR
-3 million.
The Pharmaceuticals business's net sales were EUR 469 (453) million. Net sales
of Orion's Stalevo(®) (carbidopa, levodopa and entacapone) and
Comtess(®)/Comtan(®) (entacapone) Parkinson's drugs were down by 6% at EUR 111
(118) million, which was 24% (26%) of the Pharmaceuticals business's net sales.
The net sales of other products in the portfolio were up by 7% at EUR 358 (335)
million.
The Diagnostics business's net sales were up by 3% at EUR 30 (29) million.
Operating profit
The Orion Group's operating profit was down by 6% at EUR 135 (144) million.
The Pharmaceuticals business's operating profit was down by 6% at EUR 138 (146)
million. The gross profit percentage was lower than in the comparative period
due to products with lower margins accounting for an increasing proportion of
sales, lower prices and higher production costs. Costs were increased by the
ongoing extensive investment and production facility modification projects,
which have temporarily decreased production capacity and at the same time
increased costs. As anticipated, research and development costs were slightly
higher than in the comparative period.
The Diagnostics business's operating profit was EUR 1.9 (2.9) million. The
profit was reduced by EUR 1.6 million expenses related to contraction of the
product portfolio, closure of the Turku manufacturing plant and personnel
reductions.
Operating expenses
The Group's sales and marketing expenses were EUR 100 (98) million.
R&D expenses were up by 7% at EUR 51 (48) million and accounted for 10% (10%) of
the Group's net sales. Pharmaceutical R&D expenses amounted to EUR 47 (44)
million. Research projects are reported in more detail under Pharmaceuticals in
the Business Reviews.
Administrative expenses were EUR 23 (23) million.
Other operating income and expenses increased profit by EUR 2 (1) million.
Group's profit
The Group's profit before taxes totalled EUR 134 (143) million. Basic earnings
per share were EUR 0.72 (0.77) and diluted earnings per share were EUR 0.72
(0.77). Equity per share was EUR 3.03 (2.82). The return on capital employed
before taxes (ROCE) was 41% (52%) and the return on equity after taxes (ROE)
43% (48%).
Financial position
The Group's gearing was 33% (24%) and the equity ratio 48% (55%).
The Group's total liabilities at 30 June 2013 were EUR 460 (332) million. At the
end of the period, interest-bearing liabilities amounted to EUR 278 (158)
million, including EUR 251 (127) million of long-term loans.
The Group had EUR 139 (62) million of cash and cash equivalents and money market
investments at the end of the period, which are invested in short-term interest-
bearing instruments issued by financially solid financial institutions and
corporations.
Cash flow
Cash flow from operating activities was lower than in the comparative period at
EUR 70 (93) million. The cash flow was lower because the operating profit
decreased and the amount tied up into working capital increased by more than in
the comparative period. The clear increase in inventories was mainly due to
ensuring the reliability of deliveries as the product portfolio and supply chain
were expanded. The higher amount tied up into working capital than in the
comparative period was also due to other receivables such as advanced payments
related to licensing agreements. In addition, income taxes paid were slightly
higher than in the comparative period.
Cash flow from investing activities was EUR -32 (-23) million.
Cash flow from financing activities was EUR -43 (-131) million. This change was
mainly due to the EUR 150 million bond issued in June 2013.
Capital expenditure
The Group's capital expenditure totalled EUR 37 (23) million. This comprised EUR
32 (18) million on property, plant and equipment and EUR 5 (5) million on
intangible assets.
Outlook for 2013
Net sales will be at similar level to 2012 (net sales in 2012 were EUR 980
million).
Operating profit will be slightly lower than in 2012 (operating profit in 2012
was EUR 278 million).
The Group's capital expenditure will be about EUR 80 million excluding
substantial corporate or product acquisitions (the Group's capital expenditure
in 2012 was EUR 47 million).
Basis for outlook
Competition in the Finnish market will remain intense in 2013. However, product
launches will continue to support Orion's position as market leader.
The generic competition that commenced in April 2012 in the United States has
decreased sales of Orion's Parkinson's drugs. The decrease will continue in
2013 because generic products will be in the markets during the whole year and,
in addition, the number of competitors will be greater than in 2012. US markets
accounted for about EUR 60 million of the net sales of Orion's Parkinson's drugs
in 2011 and about EUR 33 million in 2012. In addition, sales of generic
entacapone products to the United States amounted to about EUR 17 million in
2012.
The entacapone molecule patent expired in November 2012 in the main European
countries for Orion, and as a result there will be generic competitors to Comtan
and Comtess in these markets in 2013. Data protection of Stalevo will remain
valid in the European Union until October 2013 and generic competition is not
expected to commence in Europe during the current year, even though the first
generic marketing authorisation application in Europe has already been
submitted. The total sales of Orion's Parkinson's drugs in Europe are expected
to be slightly lower than in 2012. Elsewhere in the world generic competition is
not expected to have a material impact on sales volumes of these products in the
current year, but declining prices and depreciation in the exchange rate of the
Japanese yen relative to the euro will decrease sales.
Net sales and operating profit in 2012 also included EUR 10 million of non-
recurring long-term compensatory payments related to the pricing of partner
deliveries.
A slight decrease in the gross profit as percentage of net sales is anticipated.
Sales of generic products will account for a greater proportion of Orion's total
sales and price competition will remain intense in many markets. In addition,
significant ongoing investments to develop and ensure future growth, delivery
reliability and quality standards, and related reorganisation of production will
temporarily decrease production capacity and increase production costs.
Marketing expenditure will be similar to the previous year. Because the
registrations and launches of new products are projects that take more than a
year, the increases in resources and other inputs required in 2013 were planned
mainly during the previous year.
Research and development costs will be slightly higher than in 2012. They are
partly the Company's internal fixed cost items, such as salaries and maintenance
of the operating infrastructure, and partly external variable costs. External
costs arise from, among other things, long-term clinical trials, which are
typically performed in clinics located in several countries. The most important
clinical trials scheduled for 2013 are either ongoing from the previous year or
at an advanced stage of planning, therefore their cost level can be estimated
rather accurately. The accrued costs are materially affected by how the costs
arising are allocated between Orion and its collaboration partners.
The estimated costs of the ongoing patent litigations in the United States are
based on the planned timetables and work estimates. The costs due to the
litigations will depend on a number of factors, which are difficult to estimate
accurately.
Near-term risks and uncertainties relating to the outlook
Sales of Orion's Parkinson's drugs will decrease in 2013 due to generic
competition. The effects of the competition have been taken into account in the
outlook estimate.
Sales of individual products and also Orion's sales in individual markets may
vary, for example depending on the extent to which the ever-tougher price and
other competition prevailing in pharmaceutical markets in recent years will
specifically affect Orion's products. Deliveries to Novartis are based on
timetables that are jointly agreed in advance. Nevertheless, they can change,
for example as a consequence of decisions by Novartis concerning among others
adjustments of stock levels. In addition, changes in market prices and exchange
rates affect the value of deliveries to Novartis.
Most of the exchange rate risk is related to the US dollar. Typically, only less
than 15% of Orion's net sales comes from the United States. As regards
currencies in European countries, the overall effect will be abated by the fact
that Orion has organisations of its own in most of these countries, which means
that in addition to sales income, there are also costs in these currencies.
Changes in the Japanese yen exchange rate have become more important as sales of
Parkinson's drugs in Japan have increased.
Orion's currently high production capacity utilisation rate and its broad
product range may cause risks to the delivery reliability and make it more
challenging than before to maintain the very high quality standard required.
Authorities and key customers in different countries undertake regular and
detailed inspections of development and manufacturing of drugs. Any remedial
actions that may be required may at least temporarily reduce delivery
reliability.
Research projects always entail uncertainty factors that may either increase or
decrease estimated costs. The projects may progress more slowly or faster than
assumed, or they may be discontinued. Nonetheless, changes that may occur in
ongoing clinical studies are reflected in costs relatively slowly, and they are
not expected to have a material impact on earnings in the current year. Owing to
the nature of the research process, the timetables and costs of new studies that
are being started are known well in advance. They therefore typically do not
lead to unexpected changes in the estimated cost structure. Orion generally
undertakes Phase III clinical trials in collaboration with other pharmaceutical
companies. Commencement of these collaboration relationships and their structure
also materially affect the schedule and cost level of research projects.
Group's financial objectives
Orion's financial objectives are ensuring the Group's financial stability and
profitable growth.
These objectives are achieved through:
* Increasing net sales. Achievement of this objective requires continuous
investment in development of the product portfolio.
* Maintaining profitability at a good level, the aim being operating profit
that exceeds 20% of net sales.
* Keeping the equity ratio at least 50%.
Orion's dividend distribution policy
Orion's dividend distribution takes into account the distributable funds and the
capital expenditure and other financial requirements in the medium and long term
to achieve the financial objectives.
Shares and shareholders
On 30 June 2013 Orion had a total of 141,257,828 (141,257,828) shares, of which
42,272,816 (44,693,218) were A shares and 98,985,012 (96,564,610) B shares. The
Group's share capital was EUR 92,238,541.46 (92,238,541.46). At the end of June
2013 Orion held 188,991 (325,991) B shares as treasury shares. On 30 June 2013
the aggregate number of votes conferred by the A and B shares was 944,252,341
(990,102,979) excluding treasury shares.
At the end of June 2013, Orion had 53,942 (60,321) registered shareholders.
Voting rights conferred by shares
Each A share entitles its holder to twenty (20) votes at General Meetings of
Shareholders and each B share one (1) vote. However, a shareholder cannot vote
more than 1/20 of the aggregate number of votes from the different share classes
represented at the General Meetings of Shareholders. The Company itself and
Orion Pension Fund do not have the right to vote at Orion Corporation's General
Meetings of Shareholders.
Both share classes, A and B, confer equal rights to the Company's assets and
dividends.
Conversion of shares
The Articles of Association entitle shareholders to demand the conversion of
their A shares to B shares within the limitation on the maximum number of shares
of a class. In January-June 2013 a total of
994,402 shares were converted.
Trading in Orion's shares
Orion's A shares and B shares are quoted on NASDAQ OMX Helsinki in the Large Cap
group under the Healthcare sector heading under the trading codes ORNAV and
ORNBV. Trading in both of the Company's share classes commenced on 3 July 2006,
and information on trading in the Company's shares has been available since this
date.
On 30 June 2013 the market capitalisation of the Company's shares excluding
treasury shares was EUR 2,540 million.
Orion shares are also traded on various alternative trading platforms in
addition to NASDAQ OMX Helsinki.
Authorisations of the Board of Directors
Orion's Board of Directors was authorised by the Annual General Meeting on 19
March 2013 to decide on acquisition of shares in the Company and on a share
issue in which shares held by the Company can be conveyed. The authorisation to
acquire shares is valid for 18 months and the authorisation to issue shares is
valid for five years from the decision taken by the Annual General Meeting.
The Board of Directors is authorised to decide on acquisition of no more than
500,000 Orion Corporation B shares. Such shares shall be acquired at the market
price at the time of acquisition quoted in the regulated market of NASDAQ OMX
Helsinki Oy ("Stock Exchange") using funds in the Company's distributable
equity. Such shares may be acquired in the regulated market of the Stock
Exchange in a proportion not corresponding to the shareholders' holdings. The
shares shall be acquired and paid for in accordance with the rules of the Stock
Exchange and Euroclear Finland Ltd. The shares acquired can be kept, cancelled
or further conveyed by the Company. The shares can be acquired for the purpose
of developing the capital structure of the Company, for use in financing
possible corporate acquisitions or other business arrangements of the Company,
for financing capital expenditure, as part of the Company's incentive plan, or
for otherwise conveying or cancelling them. The Board of Directors shall decide
on other matters related to the acquisition of shares in the Company.
On 24 April 2013 Orion's Board of Directors decided to acquire shares in the
Company as authorised by the Annual General Meeting. According to the decision,
the Company will acquire 500,000 B shares in the Company. The shares will be
acquired in accordance with the terms of the authorisation by the Annual General
Meeting.
The Board of Directors is authorised to decide on conveyance of no more than
600,000 Orion Corporation B shares held by the Company. Such shares held by the
Company can be conveyed either against or without payment. Such shares held by
the Company can be conveyed by selling them in the regulated market of the Stock
Exchange; in a share issue placement to the Company's shareholders in proportion
to their holdings at the time of the conveyance regardless of whether they own A
or B shares; or in a share issue placement deviating from shareholders' pre-
emptive rights if there is a weighty financial reason, such as the development
of the capital structure of the Company, using the shares to finance possible
corporate acquisitions or other business arrangements of the Company, financing
capital expenditure or as part of the Company's incentive plan. The share issue
placement can be without payment only if there is an especially weighty
financial reason in the view of the Company and to the benefit of all its
shareholders. The amounts paid for shares in the Company conveyed shall be
recorded in a distributable equity fund. The Board of Directors shall decide on
other matters related to the conveyance of shares held by the Company. The
decision to authorise the share issue revoked the unexercised portion of the
outstanding share issue authorisation approved at Orion Corporation's Annual
General Meeting on 24 March 2010.
The Board of Directors is not authorised to increase the share capital or to
issue bonds with warrants or convertible bonds or stock options.
Orion Group's 2013 long-term incentive plan
In February 2013 Orion's Board of Directors decided on a new share-based
incentive plan for key persons of the Group. The Plan includes earning periods
and the Board of Directors will annually decide on the beginning and duration of
the earning periods in 2013, 2014 and 2015. The Board of Directors will decide
on the earnings criteria and on targets to be established for them at the
beginning of each earning period. The target group of the Plan consists of
approximately 35 people. The total maximum amount of rewards to be paid on the
basis of the Plan is 500,000 Orion Corporation B shares and a cash payment
corresponding to the value of the shares. The incentive plan is reported in more
detail in a stock exchange release on 5 February 2013.
Share ownership
Orion's shares are in the book-entry system maintained by Euroclear Finland, and
Euroclear Finland maintains Orion's official shareholder register.
At the end of June 2013 Orion had a total of 53,942 (60,321) registered
shareholders, of whom 95% (95%) were private individuals holding 45% (51%) of
the entire share stock and 64% (65%) of the total votes. There were altogether
50 (43) million nominee-registered shares, which was 36% (30%) of all shares,
and they conferred entitlement to 7% (6%) of the total votes.
At the end of June 2013 Orion held 188,991 (325,991) B shares as treasury
shares, which is 0.1% (0.2%) of the Company's total share stock and 0.02%
(0.03%) of the total votes.
Personnel
The average number of employees in the Orion Group in January-June 2013 was
3,541 (3,485). At the end of June 2013 the Group had a total of 3,663 (3,609)
employees, of whom 2,953 (2,888) worked in Finland and 710 (721) outside
Finland.
Salaries and other personnel expenses in January-June 2013 totalled EUR 111
(107) million.
As a result of co-operation negotiations held in Orion Diagnostica during the
review period, it has been decided to give notice of termination of employment
to a total of about 60 employees in Finland. In addition, about 20 employees
will leave their posts through for example retirement or ending of a fixed-term
contract.
Significant legal proceedings
Legal proceedings against the Sandoz companies
On 1 May 2012 Orion announced that it had been informed that the United States
District Court for the District of New Jersey had given its decision on the
patent infringement lawsuit that Orion Corporation and Hospira, Inc. filed on 4
September 2009 to enforce US Patents Nos. 4,910,214 and 6,716,867. The
respondents in the case are Sandoz Inc., Sandoz International GmbH and Sandoz
Canada Inc. (hereinafter collectively "Sandoz").
The court found that US Patent No. 4,910,214 is valid and enforceable. Sandoz is
permanently enjoined from the commercial manufacture, use, sale or offer for
sale in the United States or importation into the United States of its generic
dexmedetomidine product until such time as US Patent No. 4,910,214 expires,
including any applicable extensions. The Court also ordered that the effective
date of Sandoz's Abbreviated New Drug Application No. 91-465 shall not occur
until the expiration of Patent No. 4,910,214, including any applicable
extensions. Separately, the court found that US Patent No. 6,716,867 is invalid
as obvious.
Orion's licensee Hospira, Inc. sells Precedex(®) in the United States and in
markets outside Europe.
Orion and Hospira have filed an appeal against the decision to the court of
appeals, and so has Sandoz.
Legal proceedings against Caraco Pharmaceutical Laboratories, Ltd.
On 12 November 2010 Orion Corporation and Hospira, Inc. jointly filed a patent
infringement lawsuit in the United States against Caraco Pharmaceutical
Laboratories, Ltd. to enforce Orion's and Hospira's joint patent No. 6,716,867
valid in the United States. Gland Pharma Ltd. has since been added as a
defendant in the lawsuit.
Caraco had submitted an application for authorisation to produce and market in
the United States a generic version of Orion's proprietary drug Precedex(®)
(dexmedetomidine hydrochloride 100 µg/ml), which is marketed in the United
States by Orion's licensee Hospira.
Orion expects the costs of the legal proceedings against Caraco to be
substantially less than the costs of the entacapone patent litigation that had
previously been pending in the United States.
Legal proceedings against Mylan Pharmaceuticals Inc.
After the review period, on 25 July 2013, Orion announced that Orion Corporation
and Mylan Pharmaceuticals Inc. have executed a settlement and license agreement
to settle the lawsuit filed by Orion in the United States against Mylan
regarding Mylan's submission of an abbreviated new drug application ("ANDA") for
generic versions of Orion's Stalevo® (carbidopa/levodopa/entacapone) product.
The lawsuit was filed by Orion in the U.S. in April 2012. Under the terms of the
settlement and license agreement, Mylan shall be authorized to launch generic
versions of the Stalevo product (strengths 12.5/50/200 mg; 18.75/75/200 mg;
25/100/200 mg; 31.25/125/200 mg; 37.5/150/200 mg and 50/200/200 mg) immediately
after entry of the agreement.
Subject to the Court's approval, the lawsuit against Mylan will be dismissed and
the U.S. Patents Nos. 5,446,194, 6,500,867 and 6,797,732 shall remain in force.
Business Reviews
Pharmaceuticals
Review of human pharmaceuticals market
According to statistics collected by Finnish Pharmaceutical Data Ltd, Finnish
wholesale of human pharmaceuticals in January-June 2013 totalled EUR 1,010
(1,000) million.
Finland is the most important individual market for Orion, generating about one-
quarter of the total net sales. Orion was able to increase its sales faster than
the markets as a whole and strengthened its position as leader in marketing
pharmaceuticals in Finland. According to statistics collected by Finnish
Pharmaceutical Data Ltd, Orion's wholesale of human pharmaceuticals in Finland
in January-June 2013 amounted to EUR 116 (108) million, up by 7% compared with
the previous year. Orion's market share of Finnish pharmaceuticals markets was
11% (11%).
According to IMS Health pharmaceutical sales statistics, in the 12-month period
ending in March 2013 the total sales of Parkinson's drugs in the United States
were up by 10% at USD 783 million (USD 715 million in the previous 12-month
period). The five largest European markets for Parkinson's disease drugs were
Germany, the United Kingdom, France, Spain and Italy. In these countries, the
combined sales of Parkinson's drugs totalled EUR 965 (949) million, and the
average market growth was 2%. In Japan sales of Parkinson's drugs grew by 9% to
EUR 580 (533) million.
According to IMS Health pharmaceutical sales statistics, in the 12-month period
ending in March 2013 the total sales of Parkinson's drugs containing entacapone
were USD 188 (191) million in the United States and EUR 155 (156) million in the
five largest European markets.
The most important individual therapy area for Orion is still the treatment of
Parkinson's disease. Orion's branded Parkinson's drugs containing entacapone
(Stalevo(®), Comtess(® )and Comtan(®)) account for about a quarter of the
Group's net sales. In the United States sales of these products clearly
decreased. In Europe sales remained similar to the comparative period, and in
Japan sales continued to grow well and clearly better than the market as a
whole. According to IMS Health pharmaceutical sales statistics, in the 12-month
period ending in March 2013, sales of Orion's branded Parkinson's drugs in the
United States were down by 49% at USD 96 (191) million. Sales were EUR 154 (156)
million in the five largest markets in Europe, and grew by 14% to EUR 66 (58)
million in Japan. The market share of Orion's branded Parkinson's drugs was 12%
in the United States, on average 16% in the five largest European markets and
11% in Japan.
According to IMS Health pharmaceutical sales statistics, sales of Orion's
Precedex(®) intensive care sedative (dexmedetomidine) were up by 39% at USD 301
million in the 12-month period ending in March 2013 (USD 217 million in the
previous 12-month period). About four-fifths of the sales amounting to USD 242
(168) million were in the United States, where Precedex sales grew by 44%.
According to IMS Health pharmaceutical sales statistics, total sales of the most
common intravenous anaesthetics and intensive care sedatives (propofol,
midazolam, remifentanil and dexmedetomidine) were down by 2% in Europe in the
12-month period ending in March 2013 at EUR 472 (483) million. According to IMS
Health pharmaceutical sales statistics, in the 12-month period ending in March
2013 sales of Orion's dexdor(®) intensive care sedative (dexmedetomidine) were
up by 530% EUR to 15 (2) million in Europe.
Net sales and operating profit of the Pharmaceuticals business
Net sales of the Pharmaceuticals business in January-June 2013 were up by 4% at
EUR 469 (453) million. The operating profit of the Pharmaceuticals business was
down by 6% at EUR 138 (146) million. The operating profit of the Pharmaceuticals
business was 30% (32%) of the segment's net sales.
Net sales of Orion's top ten pharmaceuticals in January-June 2013 were EUR 226
(224) million. They accounted for 48% (50%) of the total net sales of the
Pharmaceuticals business.
Proprietary Products
The product portfolio of Proprietary Products consists of patented prescription
products in three therapy areas: central nervous system diseases, oncology and
critical care, and Easyhaler(®) pulmonary drugs.
Net sales of Proprietary Products in January-June 2013 were EUR 193 (193)
million.
Orion's branded drugs for treatment of Parkinson's disease are Stalevo(®)
(active ingredients carbidopa, levodopa and entacapone) and Comtess(®)/Comtan(®)
(entacapone), and their net sales in January-June 2013 totalled EUR 111 (118)
million. Sales of Parkinson's drugs were down by 6% and accounted for 24% (26%)
of the total net sales of the Pharmaceuticals business. Net sales from
deliveries of Stalevo and Comtan to Novartis were down by 7% at EUR 65 (70)
million. Deliveries of Stalevo to Novartis were up by 3% at EUR 45 (44) million
and deliveries of Comtan were down by 24% at EUR 20 (26) million. Total net
sales generated by Stalevo and Comtess in Orion's own sales organisation were
down by 5% at EUR 46 (48) million. Sales through Orion's own sales network were
EUR 41 (41) million for Stalevo and down by 35% at EUR 4 (7) million for
Comtess.
The US Food and Drug Administration (FDA) has an ongoing safety review of
Stalevo, which began in spring 2009. Orion is assisting the FDA in undertaking
the safety review. The FDA has requested additional data based on databases
concerning the significance of the results of the STRIDE-PD study, and
consequently Orion and Novartis have undertaken epidemiological studies and
results from them were submitted to authorities for review in the third quarter
of 2012.
Net sales of Simdax(®), a drug for treatment of acute decompensated heart
failure, in January-June 2013 were up by 4% at EUR 23 (22) million.
Total net sales of the Easyhaler(®) product family for treatment of asthma and
chronic obstructive pulmonary disease were down by 5% in January-June 2013 at
EUR 14 (14) million. Sales of Easyhaler products through Orion's own sales
network in Europe continued to grow strongly. Sales during the review period,
especially in Poland and to some extent Germany, reflected the repatriation of
rights to Easyhaler products in 2012 and the related transitional phase,
consequently total sales of the Easyhaler product family were lower than in the
comparative period.
Net sales of the Precedex(®) intensive care sedative (dexmedetomidine) were up
by 8% in January-June 2013 at EUR 23 (21) million. In the United States and
markets outside Europe the sedative is sold by Orion's partner Hospira. US
markets account for about four-fifths of net sales of Precedex.
Net sales of Orion's dexdor(®) intensive care sedative (dexmedetomidine) in
January-June 2013 were up by 146% at EUR 12 (5) million.
Specialty Products
Net sales of the Specialty Products business division's off-patent, i.e. generic
prescription drugs and self-care products in January-June 2013 were up by 6% at
EUR 188 (177) million.
Net sales of Orion's human pharmaceuticals in Finland in January-June 2013 were
up by 8% at EUR 126 (117) million. Specialty Products accounted for the majority
of sales. Orion managed to increase its sales, especially in prescription drugs.
Net sales of Orion's human pharmaceuticals in Eastern Europe and Russia in
January-June 2013 were up by 11% at altogether EUR 32 (29) million. Specialty
Products account for the majority of sales in the region.
Animal Health
In the Nordic countries and some Eastern European markets Orion itself sells
veterinary drugs, and in other markets the Company operates through partners. In
addition, in the Nordic countries Orion markets and sells veterinary drugs
manufactured by several international companies. Orion's Animal Health business
division has a strong market position in the Nordic countries, its home markets.
Net sales of the Animal Health business division in January-June 2013 were up by
1% at EUR 35 (34) million. Sales of the animal sedatives at EUR 11 (10) million
accounted for 32% (29%) of the division's net sales. Orion's animal sedatives
are Dexdomitor(®) (dexmedetomidine), Domitor(®) (medetomidine), Domosedan(®)
(detomidine) and Antisedan(®) (atipamezole).
Fermion
Fermion manufactures active pharmaceutical ingredients for Orion and other
pharmaceutical companies. Its product range comprises nearly 30 pharmaceutical
ingredients. Fermion's net sales in January-June 2013 excluding pharmaceutical
ingredients supplied for Orion's own use were up by 21% at EUR 34 (28) million
and accounted for about two-thirds of Fermion's entire net sales. Several key
products performed well, even though competition in the markets remained
intense. Capacity utilisation at Fermion's plants continued to be very high
during the review period. Capacity utilisation was increased by manufacturing
active ingredients required for development work on Orion's own proprietary
drugs, in addition to the normal product range.
Research and development projects
The Group's R&D expenses in January-June 2013 were up by 7% at EUR 51 (48)
million, of which the Pharmaceuticals business accounted for EUR 47 (44)
million. The Group's R&D expenses accounted for 10% (10%) of the Group's net
sales. R&D expenses also include expenses related to development of the current
portfolio.
Orion has ongoing projects to broaden the range of the inhalable Easyhaler(®)
drugs product family. Orion submitted an application for marketing authorisation
for a combined budesonide-formoterol formulation in Europe in March, and the
application is being processed. In this formulation, budesonide acts as an anti-
inflammatory agent and formoterol acts as a long-acting bronchodilator.
In addition, Orion has another Easyhaler research programme in progress to
develop a combined fluticasone-salmeterol formulation. In this formulation
fluticasone acts as an anti-inflammatory agent and salmeterol acts as a long-
acting bronchodilator.
Orion is collaborating with Novartis to develop Stalevo(®) drug for the Japanese
markets. Novartis submitted an application for marketing authorisation for the
product in June.
Orion is continuing to develop an androgen receptor antagonist (ODM-201) for the
treatment of advanced prostate cancer jointly with Endo Pharmaceuticals Inc.
with the objective of approval of the drug globally. Phase I/II clinical trials
on safety, efficacy and pharmacokinetics showed that initial results concerning
efficacy were promising, and the product was well tolerated with no significant
adverse events detected. Results were presented at the ESMO international
oncology congress at the end of September 2012 and ASCO GU 2012 symposium in
mid-February 2013. Development of the product is now in Phase II clinical
trials. Negotiations to find a suitable partner for collaboration on the next
phase of development of the product and commercialisation are ongoing.
Orion has completed Phase II clinical trials with an alpha-2c adrenoceptor
antagonist (ORM-12741). The trials investigated the efficacy and safety of the
drug candidate in treatment of cognitive and behavioural symptoms related to
Alzheimer's disease. Positive results from Phase IIa clinical trials were
presented at the annual meeting of the American Academy of Neurology in mid-
March 2013. Negotiations to find a suitable partner for the next development
phase are ongoing. In addition, Orion began Phase I clinical pharmacokinetic
trials with another alpha-2c adrenoceptor antagonist (ODM-102), a backup
molecule to ORM-12741.
Orion is developing a new more effective levodopa product (ODM-101) based on
optimised new formulations and doses of known compounds. Results obtained from
Phase II clinical trials in 2012 were positive, and they were presented at the
annual meeting of the American Academy of Neurology in mid-March 2013. The
search for a suitable collaboration model for the next development phase is
ongoing.
Orion has ongoing Phase I clinical safety trials initiated in summer 2012 with a
new COMT inhibitor (ODM-103). In addition, Orion has started Phase I clinical
safety trials with another new COMT inhibitor (ODM-104). ODM-103 and ODM-104 are
new molecules that enhance the therapeutic effects of levodopa used to treat
Parkinson's disease by blocking the COMT enzyme. The pre-clinical study results
indicated that they are more effective than the COMT inhibitor entacapone, which
is already in the markets.
In addition, Orion has several projects in the early research phase
investigating prostate cancer, neuropathic pain, Parkinson's disease and
Alzheimer's disease, among others.
Diagnostics
Orion Diagnostica manufactures convenient and quick in vitro diagnostic tests
and testing systems suitable for point-of-care testing. Net sales of the
Diagnostics business in January-June 2013 were up by 3% at EUR 30 (29) million.
QuikRead(®) infection tests remained the main product, with sales continuing
strong. During the review period launching of the QuikRead go(®) hsCRP+Hb test
was started. Two results, for CRP and haemoglobin, can be obtained from a single
sample with the new test.
Through the measures decided following the co-operation negotiations during the
review period under the Finnish Act on Co-operation within Undertakings, Orion
Diagnostica is streamlining its operations and improving its profitability by
among other things simplifying the product portfolio. As a result of the co-
operation negotiations, it has been decided to give notice of termination of
employment to about 60 employees, and in addition about 20 employees will leave
their posts through for example retirement or ending of a fixed-term contract.
The operating profit of the Diagnostics business was down by 37% at EUR 1.9
(2.9) million. The profit was reduced by EUR 1.6 million expenses related to
contraction of the product portfolio, closure of the Turku manufacturing plant
and personnel reductions.
Espoo, 30 July 2013
Board of Directors of Orion Corporation
Orion Corporation
Timo Lappalainen Jari Karlson
President and CEO CFO
Tables
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
EUR million Q2/13 Q2/12 Change % Q1-Q2/13 Q1-Q2/12 Change % 2012
-------------------------------------------------------------------------------
Net sales 248.0 232.8 +6.6% 497.4 480.2 +3.6% 980.4
-------------------------------------------------------------------------------
Cost of goods sold -98.9 -82.2 +20.3% -190.6 -169.0 +12.8% -350.8
-------------------------------------------------------------------------------
Gross profit 149.2 150.6 -0.9% 306.8 311.2 -1.4% 629.6
-------------------------------------------------------------------------------
Other operating income
and expenses 1.4 -0.2 +792.7% 1.7 1.3 +30.6% 6.3
-------------------------------------------------------------------------------
Sales and marketing
expenses -51.1 -49.0 +4.3% -99.7 -98.3 +1.4% -206.1
-------------------------------------------------------------------------------
R&D expenses -26.3 -24.5 +7.6% -50.9 -47.5 +7.2% -105.8
-------------------------------------------------------------------------------
Administrative expenses -12.0 -11.6 +3.6% -22.7 -22.8 -0.6% -45.7
-------------------------------------------------------------------------------
Operating profit 61.1 65.3 -6.5% 135.2 143.9 -6.0% 278.3
-------------------------------------------------------------------------------
Finance income 1.2 2.3 -48.0% 2.8 3.4 -17.0% 4.9
-------------------------------------------------------------------------------
Finance expenses -1.8 -3.1 -42.2% -4.0 -4.2 -4.1% -6.6
-------------------------------------------------------------------------------
Share of associated
companies' results 0.3 0.1 +314.1% 0.1
-------------------------------------------------------------------------------
Profit before taxes 60.5 64.5 -6.2% 134.3 143.2 -6.2% 276.6
-------------------------------------------------------------------------------
Income tax expense -14.6 -15.8 -7.4% -32.9 -35.3 -7.0% -69.7
-------------------------------------------------------------------------------
Profit for the period 45.9 48.7 -5.8% 101.4 107.8 -5.9% 206.9
-------------------------------------------------------------------------------
OTHER COMPREHENSIVE INCOME
INCLUDING TAX EFFECTS
-------------------------------------------------------------------------------
Change in value of cash
flow hedges 0.1 -0.1 0.1 -0.2 -0.2
-------------------------------------------------------------------------------
Change in value of
available-for-sale
financial assets 0.3 0.3 0.3
-------------------------------------------------------------------------------
Translation differences -1.1 0.9 -1.8 1.2 1.1
-------------------------------------------------------------------------------
Items that may be
reclassified
subsequently to profit
and loss -1.0 1.0 -1.7 1.3 1.1
-------------------------------------------------------------------------------
Items due to
remeasurement of
defined benefit plans 0.0 6.4 0.0 12.8 25.6
-------------------------------------------------------------------------------
Items that will not be
reclassified to profit
and loss 0.0 6.4 0.0 12.8 25.6
-------------------------------------------------------------------------------
Other comprehensive
income net of tax -1.0 7.4 -1.7 14.1 26.7
-------------------------------------------------------------------------------
Comprehensive income
for the period
including tax effects 44.9 56.1 -20.1% 99.8 121.9 -18.2% 233.7
-------------------------------------------------------------------------------
PROFIT ATTRIBUTABLE TO:
-------------------------------------------------------------------------------
Owners of the parent
company 45.9 48.7 -5.8% 101.4 107.8 -5.9% 206.9
-------------------------------------------------------------------------------
Non-controlling
interests 0.0 0.0 0.0 0.0 0.0
-------------------------------------------------------------------------------
COMPREHENSIVE INCOME
ATTRIBUTABLE TO:
-------------------------------------------------------------------------------
Owners of the parent
company 44.9 56.1 -20.1% 99.8 121.9 -18.2% 233.7
-------------------------------------------------------------------------------
Non-controlling
interests 0.0 0.0 0.0 0.0 0.0
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
Basic earnings per
share, EUR (1)) 0.33 0.35 -4.7% 0.72 0.77 -6.0% 1.47
-------------------------------------------------------------------------------
Diluted earnings per
share, EUR (1)) 0.33 0.35 -4.7% 0.72 0.77 -6.0% 1.47
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
Depreciation,
amortisation and
impairment 9.2 9.0 +2.6% 18.4 17.9 +2.9% 40.0
-------------------------------------------------------------------------------
Personnel expenses 56.8 53.8 +5.7% 110.9 107.0 +3.6% 214.8
-------------------------------------------------------------------------------
(1)) The figure has been calculated from the profit
attributable to the owners of the parent company.
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
ASSETS
EUR million 6/13 6/12 Change % 12/12
-------------------------------------------------------------------------------
Property, plant and equipment 223.5 196.6 +13.6% 205.3
-------------------------------------------------------------------------------
Goodwill 13.5 13.5 13.5
-------------------------------------------------------------------------------
Intangible rights 57.3 65.7 -12.8% 58.0
-------------------------------------------------------------------------------
Other intangible assets 3.7 4.6 -20.9% 4.3
-------------------------------------------------------------------------------
Investments in associates 1.7 1.4 +19.1% 1.4
-------------------------------------------------------------------------------
Available-for-sale financial assets 0.5 1.1 -55.6% 0.5
-------------------------------------------------------------------------------
Pension asset 38.5 21.5 +78.8% 38.4
-------------------------------------------------------------------------------
Deferred tax assets 1.3 1.4 -8.5% 2.0
-------------------------------------------------------------------------------
Other non-current assets 1.3 1.6 -20.8% 1.6
-------------------------------------------------------------------------------
Non-current assets total 341.3 307.6 +10.9% 325.0
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
Inventories 196.2 168.3 +16.6% 179.2
-------------------------------------------------------------------------------
Trade receivables 163.8 158.0 +3.7% 151.5
-------------------------------------------------------------------------------
Other receivables 47.9 33.0 +45.4% 34.8
-------------------------------------------------------------------------------
Money market investments 15.0
-------------------------------------------------------------------------------
Cash and cash equivalents 123.6 62.1 +98.9% 145.2
-------------------------------------------------------------------------------
Current assets total 546.5 421.4 +29.7% 510.7
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
Assets total 887.7 729.0 +21.8% 835.7
-------------------------------------------------------------------------------
EQUITY AND LIABILITIES
EUR million 6/13 6/12 Change % 12/12
-------------------------------------------------------------------------------
Share capital 92.2 92.2 92.2
-------------------------------------------------------------------------------
Expendable fund 0.5 0.5 0.5
-------------------------------------------------------------------------------
Other reserves 1.4 0.8 +66.1% 0.8
-------------------------------------------------------------------------------
Retained earnings 333.3 303.8 +9.7% 416.0
-------------------------------------------------------------------------------
Equity attributable to owners of the parent company 427.4 397.3 +7.6% 509.5
-------------------------------------------------------------------------------
Non-controlling interests 0.0 0.0 +0.6% 0.0
-------------------------------------------------------------------------------
Equity total 427.4 397.4 +7.6% 509.6
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
Deferred tax liabilities 42.5 38.0 +11.9% 42.5
-------------------------------------------------------------------------------
Pension liability 1.3 1.3 +3.8% 1.4
-------------------------------------------------------------------------------
Provisions 0.1 0.1 -16.7% 0.1
-------------------------------------------------------------------------------
Interest-bearing non-current liabilities 250.5 127.3 +96.8% 107.4
-------------------------------------------------------------------------------
Other non-current liabilities 0.6 0.6 -3.8% 0.8
-------------------------------------------------------------------------------
Non-current liabilities total 295.1 167.4 +76.3% 152.2
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
Trade payables 62.7 54.4 +15.4% 59.3
-------------------------------------------------------------------------------
Current tax liabilities 0.3 5.8 -95.0% 8.0
-------------------------------------------------------------------------------
Other current liabilities 74.5 73.8 +0.9% 77.4
-------------------------------------------------------------------------------
Provisions 0.0 0.0
-------------------------------------------------------------------------------
Interest-bearing current liabilities 27.7 30.2 -8.4% 29.3
-------------------------------------------------------------------------------
Current liabilities total 165.2 164.2 +0.6% 173.9
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
Liabilities total 460.3 331.6 +38.8% 326.1
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
Equity and liabilities total 887.7 729.0 +21.8% 835.7
-------------------------------------------------------------------------------
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
a. Share capital
b. Expendable fund
c. Other reserves
d. Items due to remeasurement of defined
benefit plans
e. Translation
differences
f. Retained earnings
g. Non-controlling interests
h. Equity total
Equity attributable to owners of the
parent company
--------------------------------------------
EUR million a. b. c. d. e. f. g. h.
-------------------------------------------------------------------------------
Equity at 31 December
2011 before change in
accounting policies 92.2 0.5 17.6 -3.8 393.4 0.0 500.0
-------------------------------------------------------------------------------
Effect of change in
accounting policies -25.4 -25.4
-------------------------------------------------------------------------------
Equity at 1 January 2012 92.2 0.5 17.6 -25.4 -3.8 393.4 0.0 474.6
-------------------------------------------------------------------------------
Profit for the period 107.8 107.8
-------------------------------------------------------------------------------
Other comprehensive
income:
-------------------------------------------------------------------------------
Change in value of cash flow
hedges -0.2 -0.2
-------------------------------------------------------------------------------
Change in value of
available-for-sale
investments 0.3 0.3
-------------------------------------------------------------------------------
Translation differences 1.2 1.2
-------------------------------------------------------------------------------
Items due to
remeasurement of defined
benefit plans 12.8 12.8
-------------------------------------------------------------------------------
Transactions with owners
-------------------------------------------------------------------------------
Dividend and capital
repayment -16.9 -183.2 -200.1
-------------------------------------------------------------------------------
Share-based incentive
plan 1.2 1.2
-------------------------------------------------------------------------------
Other adjustments -0.3 -0.3
-------------------------------------------------------------------------------
Equity at 30 June 2012 92.2 0.5 0.8 -12.6 -2.6 318.9 0.0 397.4
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
Equity at 31 December
2012 before change in
accounting policies 92.2 0.5 0.8 -2.7 420.5 0.0 511.3
-------------------------------------------------------------------------------
Effect of change in
accounting policies 0.2 -2.0 -1.8
-------------------------------------------------------------------------------
Equity at 31 December
2012 92.2 0.5 0.8 0.2 -2.7 418.5 0.0 509.6
-------------------------------------------------------------------------------
Profit for the period 101.4 101.4
-------------------------------------------------------------------------------
Other comprehensive
income:
-------------------------------------------------------------------------------
Change in value of cash flow
hedges 0.1 0.1
-------------------------------------------------------------------------------
Change in value of
available-for-sale
investments 0.0
-------------------------------------------------------------------------------
Translation differences -1.8 -1.8
-------------------------------------------------------------------------------
Items due to
remeasurement of defined
benefit plans 0.0 0.0
-------------------------------------------------------------------------------
Transactions with owners
-------------------------------------------------------------------------------
Dividend and capital
repayment -183.4 -183.4
-------------------------------------------------------------------------------
Share-based incentive
plan 1.8 1.8
-------------------------------------------------------------------------------
Other adjustments 0.4 -0.7 -0.3
-------------------------------------------------------------------------------
Equity at 30 June 2013 92.2 0.5 1.4 0.2 -4.5 337.6 0.0 427.4
-------------------------------------------------------------------------------
CONSOLIDATED STATEMENT OF CASH FLOWS
EUR million Q1-Q2/13 Q1-Q2/12 2012
-------------------------------------------------------------------------------
Operating profit 135.2 143.9 278.3
-------------------------------------------------------------------------------
Adjustments 21.6 19.1 41.5
-------------------------------------------------------------------------------
Change in working capital -44.4 -33.2 -28.9
-------------------------------------------------------------------------------
Interest paid -3.7 -3.7 -6.1
-------------------------------------------------------------------------------
Interest received 2.7 3.5 4.9
-------------------------------------------------------------------------------
Dividends received 0.2
-------------------------------------------------------------------------------
Income taxes paid -41.8 -36.6 -68.6
-------------------------------------------------------------------------------
Total net cash flow from operating activities 69.9 93.0 221.0
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
Investments in property, plant and equipment -28.6 -18.5 -42.4
-------------------------------------------------------------------------------
Investments in intangible assets -4.4 -5.2 -6.7
-------------------------------------------------------------------------------
Sales of property, plant and equipment and available-
for-sale investments 0.7 0.4 2.0
-------------------------------------------------------------------------------
Sales of intangible assets -0.1
-------------------------------------------------------------------------------
Total net cash flow from investing activities -32.3 -23.2 -47.1
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
Current loans raised 40.7 0.7 1.0
-------------------------------------------------------------------------------
Repayments of current loans -40.5 -0.5 -2.2
-------------------------------------------------------------------------------
Non-current loans raised 148.9 75.0 75.0
-------------------------------------------------------------------------------
Repayments of non-current loans -8.4 -6.6 -26.4
-------------------------------------------------------------------------------
Dividends paid and other distribution of profits -183.5 -199.8 -199.9
-------------------------------------------------------------------------------
Total net cash flow from financing activities -42.7 -131.2 -152.4
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
Net change in cash and cash equivalents -5.1 -61.5 21.5
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
Cash and cash equivalents at the beginning of the
period 145.2 123.0 123.0
-------------------------------------------------------------------------------
Foreign exchange differences -1.5 0.6 0.8
-------------------------------------------------------------------------------
Net change in cash and cash equivalents -5.1 -61.5 21.5
-------------------------------------------------------------------------------
Cash and cash equivalents at the end of the period 138.6 62.1 145.2
-------------------------------------------------------------------------------
Reconciliation of cash and cash equivalents in
statement of financial position
-------------------------------------------------------------------------------
Cash and cash equivalents in statement of financial
position at the end of the period 123.6 62.1 145.2
-------------------------------------------------------------------------------
Money market investments at the end of the period 15.0
-------------------------------------------------------------------------------
Cash and cash equivalents in the statement of cash
flows 138.6 62.1 145.2
-------------------------------------------------------------------------------
Following adoption of the amended IAS 19 Employee Benefits standard
retrospectively, the operating profit for the Q1-Q2/2012 comparative period has
been adjusted accordingly by EUR -1.3 million and the adjustments item by EUR
1.3 million. The operating profit for the 2012 comparative period has been
adjusted by EUR -2.6 million and the adjustments item by EUR 2.6 million.
CHANGES IN PROPERTY, PLANT AND EQUIPMENT
EUR million 6/13 6/12 12/12
-------------------------------------------------------------------
Carrying amount at the beginning of the period 205.3 190.7 190.7
-------------------------------------------------------------------
Additions 31.9 18.3 40.1
-------------------------------------------------------------------
Disposals -1.0 -0.4 -1.1
-------------------------------------------------------------------
Depreciation and impairments -12.6 -12.0 -24.5
-------------------------------------------------------------------
Carrying amount at the end of the period 223.5 196.6 205.3
-------------------------------------------------------------------
CHANGES IN INTANGIBLE ASSETS (EXCLUDING GOODWILL)
EUR million 6/13 6/12 12/12
-----------------------------------------------------------------
Carrying amount at the beginning of the period 62.3 71.3 71.3
-----------------------------------------------------------------
Additions 4.5 5.0 6.6
-----------------------------------------------------------------
Disposals -0.0 -0.0 -0.0
-----------------------------------------------------------------
Amortisation and impairments -5.8 -5.9 -15.5
-----------------------------------------------------------------
Carrying amount at the end of the period 61.1 70.4 62.3
-----------------------------------------------------------------
COMMITMENTS AND CONTINGENCIES
EUR million 6/13 6/12 12/12
--------------------------------------------------------------------------
CONTINGENCIES FOR OWN LIABILITIES
--------------------------------------------------------------------------
Mortgages on land and buildings 32.0 41.0 41.0
--------------------------------------------------------------------------
of which those to Orion Pension Fund 9.0 9.0
--------------------------------------------------------------------------
Guarantees 1.7 1.5 1.5
--------------------------------------------------------------------------
OTHER LIABILITIES
--------------------------------------------------------------------------
Leasing liabilities (excluding finance lease contracts) 6.2 5.6 6.5
--------------------------------------------------------------------------
Other liabilities 0.3 0.3 0.3
--------------------------------------------------------------------------
DERIVATIVES
EUR million 6/13 6/12 12/12
--------------------------------------------------------------
CURRENCY FORWARD CONTRACTS AND CURRENCY SWAPS
--------------------------------------------------------------
Fair value, EUR million -0.1 -0.1 0.3
--------------------------------------------------------------
Nominal value, EUR million 48.3 46.8 52.0
--------------------------------------------------------------
CURRENCY OPTIONS
--------------------------------------------------------------
Fair value, EUR million 0.1 0.0 0.2
--------------------------------------------------------------
Nominal value, EUR million 56.3 38.9 51.3
--------------------------------------------------------------
INTEREST RATE SWAPS
--------------------------------------------------------------
Fair value, EUR million -0.1 -0.1 -0.3
--------------------------------------------------------------
Nominal value, EUR million 20.5 24.1 22.3
--------------------------------------------------------------
CROSS CURRENCY SWAPS
--------------------------------------------------------------
Fair value, EUR million -0.1 -0.1 0.2
--------------------------------------------------------------
Nominal value, EUR million 4.8 14.3 9.6
--------------------------------------------------------------
ELECTRICITY DERIVATIVES
--------------------------------------------------------------
Fair value, EUR million -0.7 -0.6 -0.6
--------------------------------------------------------------
Nominal amount, GWh 83 140 110
--------------------------------------------------------------
DERIVATIVE CATEGORIES USING FAIR VALUE HIERARCHY
EUR million Level 1 Level 2 Level 3 Total
-------------------------------------------------------------------------------
Currency forward contracts and
currency swaps -0.1 -0.1
-------------------------------------------------------------------------------
Currency options 0.1 0.1
-------------------------------------------------------------------------------
Interest rate swaps -0.1 -0.1
-------------------------------------------------------------------------------
Cross currency swaps -0.1 -0.1
-------------------------------------------------------------------------------
Electricity derivatives -0.7 -0.7
-------------------------------------------------------------------------------
All derivatives are OTC derivatives, and market quotations available at the
end of the reporting period have been used as their fair value.
In the Group the principle is applied that transfers between levels of fair
value hierarchy are recognised on the date on which the event triggering the
transfer has occurred.
No transfers between levels occurred during the reporting period.
RELATED PARTY TRANSACTIONS
EUR million Q1-Q2/13 Q1-Q2/12 2012
----------------------------------------------------------
Management's employment benefits 4.6 3.5 4.4
----------------------------------------------------------
Operating segment performance
NET SALES BY BUSINESS DIVISION
EUR million Q2/13 Q2/12 Change % Q1-Q2/13 Q1-Q2/12 Change % 2012
-------------------------------------------------------------------------------
Pharmaceuticals 235.0 220.1 +6.8% 469.2 452.6 +3.7% 928.9
-------------------------------------------------------------------------------
Proprietary
Products 92.7 94.1 -1.5% 193.1 193.1 403.7
-------------------------------------------------------------------------------
Specialty
Products 92.0 86.7 +6.1% 187.7 176.9 +6.1% 367.2
-------------------------------------------------------------------------------
Animal Health 19.8 15.9 +23.9% 34.5 34.2 +1.1% 69.2
-------------------------------------------------------------------------------
Fermion 20.9 12.3 +69.9% 34.3 28.3 +21.1% 48.4
-------------------------------------------------------------------------------
Contract
manufacturing
and other 9.6 11.0 -13.0% 19.6 20.2 -2.6% 40.5
-------------------------------------------------------------------------------
Diagnostics 14.0 13.4 +4.3% 29.9 28.9 +3.2% 54.1
-------------------------------------------------------------------------------
Group items -0.9 -0.7 +24.6% -1.7 -1.4 +20.7% -2.7
-------------------------------------------------------------------------------
Group total 248.0 232.8 +6.6% 497.4 480.2 +3.6% 980.4
-------------------------------------------------------------------------------
OPERATING PROFIT BY BUSINESS AREA
EUR million Q2/13 Q2/12 Change % Q1-Q2/13 Q1-Q2/12 Change % 2012
----------------------------------------------------------------------
Pharmaceuticals 64.4 67.5 -4.6% 138.3 146.3 -5.5% 286.5
----------------------------------------------------------------------
Diagnostics -0.4 0.5 -183.2% 1.9 2.9 -36.9% 2.3
----------------------------------------------------------------------
Group items -2.9 -2.7 +8.6% -4.9 -5.4 -8.5% -10.6
----------------------------------------------------------------------
Group total 61.1 65.3 -6.5% 135.2 143.9 -6.0% 278.3
----------------------------------------------------------------------
NET SALES BY ANNUAL QUARTERS
2013 2012 2011
+-----------+-----------------------+-----------+
EUR million | Q2 Q1| Q4 Q3 Q2 Q1| Q4 Q3|
----------------+-----------+-----------------------+-----------+
Pharmaceuticals|235.0 234.2|242.1 234.2 220.1 232.5|223.8 199.8|
----------------+-----------+-----------------------+-----------+
Diagnostics | 14.0 15.9| 13.1 12.1 13.4 15.5| 12.9 11.3|
----------------+-----------+-----------------------+-----------+
Group items | -0.9 -0.8| -0.8 -0.5 -0.7 -0.6| -0.6 -0.5|
----------------+-----------+-----------------------+-----------+
Group total |248.0 249.4|254.4 245.8 232.8 247.4|236.1 210.7|
----------------+-----------+-----------------------+-----------+
OPERATING PROFIT BY ANNUAL QUARTERS
2013 2012 2011
+---------+-------------------+---------+
EUR million | Q2 Q1| Q4 Q3 Q2 Q1| Q4 Q3|
----------------+---------+-------------------+---------+
Pharmaceuticals|64.4 73.9|62.2 78.0 67.5 78.8|61.4 66.8|
----------------+---------+-------------------+---------+
Diagnostics |-0.4 2.3|-0.6 0.0 0.5 2.5| 0.7 0.8|
----------------+---------+-------------------+---------+
Group items |-2.9 -2.0|-2.9 -2.3 -2.7 -2.7|-2.5 -2.1|
----------------+---------+-------------------+---------+
Group total |61.1 74.1|58.8 75.6 65.3 78.6|59.6 65.4|
----------------+---------+-------------------+---------+
GEOGRAPHICAL BREAKDOWN OF NET SALES BY ANNUAL QUARTERS
2013 2012 2011
+-----------+-----------------------+-----------+
EUR million | Q2 Q1| Q4 Q3 Q2 Q1| Q4 Q3|
--------------+-----------+-----------------------+-----------+
Finland | 67.7 67.8| 67.3 63.3 62.7 64.0| 61.7 60.1|
--------------+-----------+-----------------------+-----------+
Scandinavia | 34.5 32.5| 33.3 30.3 30.3 32.4| 28.5 28.1|
--------------+-----------+-----------------------+-----------+
Other Europe | 83.6 75.7| 68.1 76.5 79.2 78.7| 79.6 71.5|
--------------+-----------+-----------------------+-----------+
North America| 33.6 34.5| 54.7 27.1 30.4 38.4| 36.0 24.0|
--------------+-----------+-----------------------+-----------+
Other markets| 28.8 38.8| 31.0 48.6 30.2 33.9| 30.3 26.9|
--------------+-----------+-----------------------+-----------+
Group total |248.0 249.4|254.4 245.8 232.8 247.4|236.1 210.7|
--------------+-----------+-----------------------+-----------+
Business reviews
KEY FIGURES FOR PHARMACEUTICALS BUSINESS
EUR million Q2/13 Q2/12 Change % Q1-Q2/13 Q1-Q2/12 Change % 2012
-------------------------------------------------------------------------------
Net sales 235.0 220.1 +6.8% 469.2 452.6 +3.7% 928.9
-------------------------------------------------------------------------------
Operating profit 64.4 67.5 -4.6% 138.3 146.3 -5.5% 286.5
-------------------------------------------------------------------------------
% of net sales 27.4% 30.7% 29.5% 32.3% 30.8%
-------------------------------------------------------------------------------
R&D expenses 24.2 22.3 +8.3% 46.6 43.6 +6.8% 97.6
-------------------------------------------------------------------------------
% of net sales 10.3% 10.1% 9.9% 9.6% 10.5%
-------------------------------------------------------------------------------
Capital expenditure 16.7 13.7 +22.3% 35.2 20.9 +68.4% 42.0
-------------------------------------------------------------------------------
% of net sales 7.1% 6.2% 7.5% 4.6% 4.5%
-------------------------------------------------------------------------------
Sales revenue from
proprietary products 98.2 97.9 +0.4% 206.3 204.6 +0.8% 429.0
-------------------------------------------------------------------------------
Assets 681.8 605.1 627.3
-------------------------------------------------------------------------------
Liabilities 127.8 120.1 128.4
-------------------------------------------------------------------------------
Personnel at the end of
the period 3,298 3,245 3,123
-------------------------------------------------------------------------------
TOP TEN BEST-SELLING PHARMACEUTICAL PRODUCTS
EUR million Q2/13 Q2/12 Change % Q1-Q2/13 Q1-Q2/12 Change % 2012
-------------------------------------------------------------------------------
Stalevo(®), Comtess(®)
and Comtan(®)
(Parkinson's disease) 50.5 54.9 -7.9% 110.8 118.1 -6.2% 250.1
-------------------------------------------------------------------------------
Precedex(®) (intensive
care sedative) 11.0 10.9 +0.7% 23.0 21.2 +8.3% 45.3
-------------------------------------------------------------------------------
Simdax(®) (acute
decompensated heart
failure) 11.7 11.4 +3.1% 22.6 21.8 +3.7% 43.6
-------------------------------------------------------------------------------
Easyhaler(®) product
family
(asthma, COPD) 7.3 7.3 +1.2% 13.5 14.2 -4.9% 26.8
-------------------------------------------------------------------------------
dexdor(®) (intensive
care sedative) 6.2 2.6 +138.0% 11.9 4.8 +146.4% 13.0
-------------------------------------------------------------------------------
Burana(®) (inflammatory
pain) 5.4 5.7 -3.9% 11.2 11.4 -1.7% 23.3
-------------------------------------------------------------------------------
Dexdomitor(®),
Domitor(®), Domosedan(®)
and Antisedan(®) (animal
sedatives) 6.1 3.7 +65.2% 11.0 10.0 +9.2% 22.8
-------------------------------------------------------------------------------
Marevan(®)
(anticoagulant) 4.1 3.9 +4.3% 8.1 8.3 -1.8% 15.8
-------------------------------------------------------------------------------
Divina(®) range
(menopausal symptoms) 3.9 4.3 -9.3% 7.3 8.1 -9.4% 15.5
-------------------------------------------------------------------------------
Fareston(®) (breast
cancer) 1.5 2.9 -47.7% 6.2 6.4 -2.4% 11.9
-------------------------------------------------------------------------------
Total 107.8 107.5 +0.3% 225.6 224.4 +0.6% 468.2
-------------------------------------------------------------------------------
Share of pharmaceutical
net sales 46% 49% 48% 50% 50%
-------------------------------------------------------------------------------
KEY FIGURES FOR DIAGNOSTICS BUSINESS
EUR million Q2/13 Q2/12 Change % Q1-Q2/13 Q1-Q2/12 Change % 2012
-------------------------------------------------------------------------------
Net sales 14.0 13.4 +4.3% 29.9 28.9 +3.2% 54.1
-------------------------------------------------------------------------------
Operating profit -0.4 0.5 -183.2% 1.9 2.9 -36.9% 2.3
-------------------------------------------------------------------------------
% of net sales 2.9% 3.6% 6.2% 10.1% 4.3%
-------------------------------------------------------------------------------
R&D expenses 2.2 2.1 +2.9% 4.5 4.0 +14.2% 8.3
-------------------------------------------------------------------------------
% of net sales 15.8% 16.0% 15.1% 13.7% 15.4%
-------------------------------------------------------------------------------
Capital expenditure 0.5 1.2 -60.6% 1.3 2.3 -44.7% 4.2
-------------------------------------------------------------------------------
% of net sales 3.5% 9.2% 4.3% 8.0% 7.7%
-------------------------------------------------------------------------------
Assets 49.7 45.5 47.2
-------------------------------------------------------------------------------
Liabilities 16.0 16.0 16.2
-------------------------------------------------------------------------------
Personnel at the end of
the period 341 338 340
-------------------------------------------------------------------------------
Information on Orion's shares
BASIC SHARE INFORMATION 30 JUNE 2013
A shares B shares Total
-------------------------------------------------------------------------------
Trading code on NASDAQ OMX Helsinki ORNAV ORNBV
-------------------------------------------------------------------------------
Listing day 1 July 2006 1 July 2006
-------------------------------------------------------------------------------
ISIN code FI0009014369 FI0009014377
-------------------------------------------------------------------------------
ICB code 4500 4500
-------------------------------------------------------------------------------
Reuters code ORNAV.HE ORNBV.HE
-------------------------------------------------------------------------------
Bloomberg code ORNAV.FH ORNBV.FH
-------------------------------------------------------------------------------
Share capital, EUR million 28.2 64.0 92.2
-------------------------------------------------------------------------------
Counter book value per share, EUR 0.65 0.65
-------------------------------------------------------------------------------
Total number of shares 42,272,816 98,985,012 141,257,828
-------------------------------------------------------------------------------
% of total share stock 30% 70% 100%
-------------------------------------------------------------------------------
Number of treasury shares 188,991 188,991
-------------------------------------------------------------------------------
Total number of shares excluding
treasury shares 42,272,816 98,796,021 141,068,837
-------------------------------------------------------------------------------
Minimum number of shares 1
-------------------------------------------------------------------------------
Maximum number of A and B shares, and
maximum
number of all shares 500,000,000 1,000,000,000 1,000,000,000
-------------------------------------------------------------------------------
Votes per share 20 1
-------------------------------------------------------------------------------
Number of votes excluding treasury
shares 845,456,320 98,796,021 944,252,341
-------------------------------------------------------------------------------
% of total votes 90% 10% 100%
-------------------------------------------------------------------------------
Total number of shareholders 18,117 41,991 53,942
-------------------------------------------------------------------------------
A shares and B shares confer equal rights to the Company's assets and
dividends.
INFORMATION ON TRADING ON NASDAQ OMX HELSINKI 1 JANUARY - 30 JUNE 2013
A shares B shares Total
------------------------------------------------------------------------------
Shares traded 1,965,375 45,827,603 47,792,978
------------------------------------------------------------------------------
% of the total number of shares 4.6% 46.6% 33.8%
------------------------------------------------------------------------------
Trading volume, EUR million 41.9 969.4 1,011.3
------------------------------------------------------------------------------
Closing quotation on 31 December 2012, EUR 22.05 22.18
------------------------------------------------------------------------------
Lowest quotation, EUR (A and B 24 June 2013) 17.30 17.31
------------------------------------------------------------------------------
Average quotation, EUR 21.32 21.15
------------------------------------------------------------------------------
Highest quotation, EUR (A and B 8 March 2013) 24.42 24.58
------------------------------------------------------------------------------
Closing quotation on 30 June 2013, EUR 17.96 18.02
------------------------------------------------------------------------------
Market capitalisation on 30 June 2013
excluding treasury shares, EUR million 759.2 1,780.3 2,539.5
------------------------------------------------------------------------------
PERFORMANCE PER SHARE
Q2/13 Q2/12 Change % Q1-Q2/13 Q1-Q2/12 Change % 2012
-------------------------------------------------------------------------------
Basic earnings per
share, EUR 0.33 0.35 -5.9% 0.72 0.77 -6.0% 1.47
-------------------------------------------------------------------------------
Diluted earnings
per share, EUR 0.33 0.35 -5.9% 0.72 0.77 -6.0% 1.47
-------------------------------------------------------------------------------
Cash flow per
share before
financial items,
EUR 0.19 0.23 -14.3% 0.27 0.50 -46.2% 1.23
-------------------------------------------------------------------------------
Equity per share,
EUR 3.03 2.82 +7.5% 3.62
-------------------------------------------------------------------------------
Average number of
shares excluding
treasury shares,
1,000 shares 141,069 140,932 141,023 140,897 140,915
-------------------------------------------------------------------------------
Appendices
Reporting
Orion Corporation is the parent company of the Orion Group. The Group consists
of two business areas, or operating segments, and five business divisions. Orion
reports on its operations segmentally.
* Pharmaceuticals business
* Proprietary Products (patented prescription products for three therapy
areas)
* Specialty Products (off-patent, generic prescription products and self-
care products)
* Animal Health (veterinary products for pets and production animals)
* Fermion (active pharmaceutical ingredients for Orion and other
companies)
* Diagnostics business
* Orion Diagnostica (diagnostic test systems for point-of-care in
healthcare and hygiene tests for industry).
Contract manufacturing and other, i.e. manufacturing for other companies, is
included in the Pharmaceuticals business segment, but it is not a separate
business division, it is part of the Group's Supply Chain organisation.
Accounting policies
This Interim Report has been prepared in accordance with the IAS 34 Interim
Financial Reporting standard. The same accounting policies as for the Financial
Statements for 2012 have been applied in preparing the Interim Report, except
for amendments to existing IFRS and IAS standards endorsed by the EU that have
been adopted as of 1 January 2013. The amendments to IFRS standards had no
effect on the Consolidated Financial Statements. The effects of the amendment to
the IAS 19 standard on the Consolidated Financial Statements are described in
more detail below.
Effect of amendment to IAS 19 Employee Benefits standard on the Orion Group's
Consolidated Financial Statements
The Orion Group has changed its accounting procedure concerning defined benefit
plans to comply with the requirements of the amended IAS 19 Employee Benefits
standard. The Group has stopped using the corridor approach and, in accordance
with the amended standard, recognises all amounts arising from remeasurement of
defined benefit plan assets directly into the components of other comprehensive
income. The Group continues the accounting procedure of function-based
recognition of net interest arising from the plan assets through service costs
above the operating profit. The accounting policy in accordance with the amended
standard has been applied retroactively as of 1 January 2013.
The restated figures in the Orion Group's Consolidated Statement of
Comprehensive Income and Statement of Financial Position and key figures for the
financial year 2012 are presented by annual quarters in the table appended to
this Interim Report. The amendment to the IAS 19 standard decreased the
operating profit for the 2012 financial year by EUR 2.6 million. The net effect
of the amendment on equity at 31 December 2012 was EUR -1.8 million. The
amendment decreased the equity at 1 January 2012 by EUR 25.4 million, but
increased the equity during the 2012 financial year by EUR 23.6 million.
The policies and calculation methods applied during the period can be found on
the Orion website at www.orion.fi/en/investors/.
Restated figures in Consolidated Statement of Comprehensive Income and Statement
of Financial Position and other key figures for 2012
Q1/12 Q1-Q2/12
Reported Reported
earlier Restated earlier Restated
-------------------------------------------------------------------------------
Operating profit, EUR million 79.3 78.6 145.2 143.9
-------------------------------------------------------------------------------
% of net sales 32.0% 31.8% 30.2% 30.0%
-------------------------------------------------------------------------------
Profit before taxes, EUR million 79.3 78.7 144.5 143.2
-------------------------------------------------------------------------------
% of net sales 32.1% 31.8% 30.1% 29.8%
-------------------------------------------------------------------------------
Income tax expense, EUR million 19.7 19.5 35.6 35.3
-------------------------------------------------------------------------------
R&D expenses, EUR million 22.8 23.1 47.1 47.5
-------------------------------------------------------------------------------
% of net sales 9.2% 9.3% 9.8% 9.9%
-------------------------------------------------------------------------------
Cost of goods sold, EUR million 86.6 86.8 168.5 169.0
-------------------------------------------------------------------------------
% of net sales 35.0% 35.1% 35.1% 35.2%
-------------------------------------------------------------------------------
Sales and marketing expenses,
EUR million 49.2 49.3 98.1 98.3
-------------------------------------------------------------------------------
% of net sales 19.9% 19.9% 20.4% 20.5%
-------------------------------------------------------------------------------
Administrative expenses,
EUR million 11.1 11.2 22.6 22.8
-------------------------------------------------------------------------------
% of net sales 4.5% 4.5% 4.7% 4.7%
-------------------------------------------------------------------------------
Profit for the period, EUR million 59.6 59.1 108.8 107.8
-------------------------------------------------------------------------------
Other comprehensive income net of tax, EUR
million 0.2 6.6 1.3 14.1
-------------------------------------------------------------------------------
Pension assets, EUR million 38.0 13.0 38.7 21.5
-------------------------------------------------------------------------------
Pension liabilities, EUR million 0.5 1.2 0.5 1.3
-------------------------------------------------------------------------------
Deferred tax liabilities, EUR million 41.6 35.3 42.4 38.0
-------------------------------------------------------------------------------
Equity total, EUR million 360.5 341.1 410.9 397.4
-------------------------------------------------------------------------------
Assets total, EUR million 905.2 880.1 746.1 729.0
-------------------------------------------------------------------------------
Equity ratio, % 39.8% 38.8% 55.1% 54.5%
-------------------------------------------------------------------------------
Gearing, % -20.0% -21.2% 23.2% 24.0%
-------------------------------------------------------------------------------
Non-interest-bearing liabilities,
EUR million 380.9 375.4 177.5 174.1
-------------------------------------------------------------------------------
ROCE (before taxes), % 57.8% 58.4% 51.4% 51.6%
-------------------------------------------------------------------------------
ROE (after taxes), % 55.4% 56.2% 47.8% 48.1%
-------------------------------------------------------------------------------
Basic earnings per share, EUR 0.42 0.42 0.77 0.77
-------------------------------------------------------------------------------
Diluted earnings per share, EUR 0.42 0.42 0.77 0.77
-------------------------------------------------------------------------------
Equity per share, EUR 2.56 2.42 2.92 2.82
-------------------------------------------------------------------------------
Personnel expenses, EUR million 52.6 53.3 105.7 107.0
-------------------------------------------------------------------------------
Q1-Q3/12 Q1-Q4/12
Reported Reported
earlier Restated earlier Restated
-------------------------------------------------------------------------------
Operating profit, EUR million 221.5 219.5 280.9 278.3
-------------------------------------------------------------------------------
% of net sales 30.5% 30.2% 28.7% 28.4%
-------------------------------------------------------------------------------
Profit before taxes, EUR million 220.5 218.5 279.3 276.6
-------------------------------------------------------------------------------
% of net sales 30.4% 30.1% 28.5% 28.2%
-------------------------------------------------------------------------------
Income tax expense, EUR million 54.5 54.0 70.4 69.7
-------------------------------------------------------------------------------
R&D expenses, EUR million 73.2 73.9 104.8 105.8
-------------------------------------------------------------------------------
% of net sales 10.1% 10.2% 10.7% 10.8%
-------------------------------------------------------------------------------
Cost of goods sold, EUR million 253.7 254.4 350.0 350.8
-------------------------------------------------------------------------------
% of net sales 34.9% 35.0% 35.7% 35.8%
-------------------------------------------------------------------------------
Sales and marketing expenses,
EUR million 147.5 147.8 205.7 206.1
-------------------------------------------------------------------------------
% of net sales 20.3% 20.4% 21.0% 21.0%
-------------------------------------------------------------------------------
Administrative expenses,
EUR million 32.2 32.5 45.3 45.7
-------------------------------------------------------------------------------
% of net sales 4.4% 4.5% 4.6% 4.7%
-------------------------------------------------------------------------------
Profit for the period, EUR million 166.0 164.5 208.9 206.9
-------------------------------------------------------------------------------
Other comprehensive income net of tax, EUR
million 1.9 21.1 1.1 26.7
-------------------------------------------------------------------------------
Pension assets, EUR million 39.3 30.1 39.6 38.4
-------------------------------------------------------------------------------
Pension liabilities, EUR million 0.5 1.4 0.3 1.4
-------------------------------------------------------------------------------
Deferred tax liabilities, EUR million 42.1 39.6 43.1 42.5
-------------------------------------------------------------------------------
Equity total, EUR million 468.7 461.1 511.3 509.6
-------------------------------------------------------------------------------
Assets total, EUR million 791.9 782.7 836.9 835.7
-------------------------------------------------------------------------------
Equity ratio, % 59.2% 58.9% 61.1% 61.0%
-------------------------------------------------------------------------------
Gearing, % 7.6% 7.7% -1.7% -1.7%
-------------------------------------------------------------------------------
Non-interest-bearing liabilities,
EUR million 173.0 171.7 189.0 189.5
-------------------------------------------------------------------------------
ROCE (before taxes), % 50.0% 49.9% 46.2% 45.9%
-------------------------------------------------------------------------------
ROE (after taxes), % 45.7% 45.6% 41.3% 41.0%
-------------------------------------------------------------------------------
Basic earnings per share, EUR 1.18 1.17 1.48 1.47
-------------------------------------------------------------------------------
Diluted earnings per share, EUR 1.18 1.17 1.48 1.47
-------------------------------------------------------------------------------
Equity per share, EUR 3.33 3.27 3.63 3.62
-------------------------------------------------------------------------------
Personnel expenses, EUR million 152.8 154.8 212.1 214.8
-------------------------------------------------------------------------------
Other matters
The data in this financial review are not audited.
The figures in parentheses are for the corresponding period of the previous
year. All the figures in this report have been rounded, which is why the total
sums of individual figures may differ from the total sums shown.
CALCULATION OF THE KEY FIGURES
Profit before taxes + Interest
= and other finance expenses
Return on capital employed (ROCE), % ----------------------------------x 100
Total assets - Non-interest-
bearing liabilities (average
during the period)
Profit for the period
Return on equity (ROE), % =----------------------------------x 100
Total equity (average during the
period)
Equity
=----------------------------------
Equity ratio, % Total assets - Advances received x 100
Interest-bearing liabilities -
Cash and cash equivalents -
= Money market investments x 100
Gearing, % ----------------------------------
Equity
Profit available for the owners
= of the parent company
Earnings per share, EUR ----------------------------------
Average number of shares during
the period, excluding treasury
shares
Cash flow from operating
activities + Cash flow from
Cash flow per share before financial = investing activities
items, EUR ----------------------------------
Average number of shares during
the period, excluding treasury
shares
Equity of the owners of the
= parent company
Equity per share, EUR ----------------------------------
Number of shares at the end of
the period, excluding treasury
shares
Total EUR value of shares traded
=----------------------------------
Average share price, EUR Average number of traded shares
during the period
Number of shares at the end of
Market capitalisation, EUR million = the period × Closing quotation
of the period
Publisher:
Orion Corporation
www.orion.fi/
www.twitter.com/OrionCorpIR
Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical ingredients
and diagnostic tests. The company is continuously developing new drugs and
treatment methods. Pharmaceutical R&D focuses on central nervous system drugs,
oncology and critical care drugs, and Easyhaler(®) pulmonary drugs.
Orion's net sales in 2012 amounted to EUR 980 million and the Company had about
3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.
[HUG#1719681]
